Dexmedetomidine is effective as both an analgesic and a sedative due to its qualities as a selective alpha 2 (2) adrenergic agonist. These features allow it to have these dual effects. When used with local anesthetics, drowsiness are two possible side effects of the pharmacologically active dextroisomer of medetomidine, which is dexmedetomidine. It may be utilized without the user needing to worry about having any unfavorable consequences on their respiratory system. Because of its unique mode of action, it differs from other drugs, such as clonidine, which treats the same condition. There is presently not enough evidence to advocate the use of dexmedetomidine for TAP block, despite the fact that it has been demonstrated to be an effective adjuvant in other types of nerve blocks. We conducted research to determine whether or not the anesthetic potency of ropivacaine, together with its extended duration of action and good toxicity profile, makes it a preferable option to bupivacaine and dexmedetomidine for TAP block in patients having laparoscopic cholecystectomy. This was done with the intention of ropivacaine's ability to provide post-operative analgesia. inquiries into the aforementioned Patients who received an ultrasound-guided TAP block with ropivacaine in Group II (ultrasound-guided TAP block with ropivacaine) reported significantly less discomfort 10, 30, and 1 hour after the treatment than patients who received a bupivacaine block in Group I (bupivacaine block). However, neither medicine was better to the other in terms of post-operative analgesia and the cumulative need for rescue analgesics after 24 hours of treatment. In the first hour following surgery, the analgesia provided by ropivacaine administered by an ultrasound-guided TAP block is on par with that provided by bupivacaine. On the other hand, when looking at the overall number of times a rescue analgesic is required in a particular day, neither of these medicines performs any better than the other.